Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q3 2016 call → NOThe question asks whether management describes that the company's successive engagements of the same kind are coming in at progressively larger size. I need to look for evidence in the transcript where management contrasts the size/scope of what they're landing now versus before, for the same offering. Looking through the transcript, I see discussions about: - Margetuximab Phase 3 SOPHIA trial enrollment - B7-H3 franchise programs - MGD009, MGD006, MGD007 trials - MGD010 returned from Takeda - MGD012 IND cleared - MGD013 and MGD014 INDs planned for 2017 The discussion is mostly about clinical trial progress, enrollment, and pipeline updates. There's no discussion about deals, orders, contracts, or business engagements getting progressively larger. The discussion about Takeda returning MGD010 rights is about regaining rights, not about larger deals. The financial discussion mentions revenues from collaborative agreements but doesn't describe escalating deal sizes. The company talks about its pipeline and clinical programs but nothing about successive engagements of the same kind coming in at progressively larger size. There's no mention of deal sizes, contract values, or scope of partnerships escalating. The transcript is focused on clinical development progress, not on business development deal sizes. Answer: NO
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.